## HIGHLIGHTS

433 Selected Articles from This Issue

## SPECIAL FEATURES

### CCR Translations

435 Inevitable Progress—Relying on the Immune System, Not Chance

Assuntina G. Sacco and Ezra E.W. Cohen

See related article, p. 468

438 Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?

Van K. Morris and Thomas J. George

See related article, p. 507

### CCR Drug Updates

441 FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Elaine Chang, Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Elias Zahalka, Tiffany K. Ricks, Jeanne Fourie Zirkelbach, Junshan Qiu, Jingyu Yu, Xiao Hong Chen, Vishal Bhatnagar, Kirsten B. Goldberg, Shenghui Tang, Paul G. Kluetz, Richard Pzdur, Amna Ibrahim, Julia A. Beaver, and Laleh Amiri-Kordestani

446 FDA Approval Summary: Nivolumab in Combination with Ipiilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Erica C. Nakajima, Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Youwei Bi, Hisham Qosa, Jian Jin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenzhan Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, and Shun Lu

## CLINICAL TRIALS: IMMUNOTHERAPY

### Clinical Trials: Targeted Therapy

452 A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek M.E. Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Tamir, Leah Henegar, Yao Shen, Mariano J. Alvarez, Andrea Califano, Yosef Landesman, Michael G. Kaufman, Sharon Shacham, and Morten Mau-Sørensen

461 Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenzhan Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, and Shun Lu

468 Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck


See related commentary, p. 435

479 Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors


489 Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Xinan Sheng, Haige Chen, Bin Hu, Xudong Yao, Ziling Liu, Xin Yao, Hongqian Guo, Yi Hu, Zhigang Ji, Hong Luo, Benkang Shi, Jiyuan Liu, Jin Wu, Fangjian Zhou, Zhisong He, Jinhai Fan, Weifeng Wang, Hui Feng, Sheng Yao, Patricia Keegan, Yiran Huang, and Jun Guo

498 Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase I/II Study

Katherine E. Miller, Kevin A. Cassidy, Justin C. Roth, Jennifer Clements, Kathleen M. Schieffer, Kristen Leraas, Anthony R. Miller, Nripsesh Prasad, Jianmei W. Leavenworth, Inmaculada B. Aban, Richard J. Whitney, G. Yancey Gillespie, Elaine R. Mardis, and James M. Markert
## TABLE OF CONTENTS

### PRECISION MEDICINE AND IMAGING

**507** Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Roselló, Anders Husted Madsen, Uffe S. Love, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, and Claus Lindbjerg Andersen

See related commentary, p. 438

**518** A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Isabelle Girault, Julien Adam, Shensi Shen, Séverine Roy, Caroline Brard, Sara Faouzi, Emilie Routier, Jérémie Lupu, Sarah Warren, Kristina Song, SuFey Ong, Pascale Maille, Jean-Yves Scoazec, Stéphanie Vagner, and Caroline Robert

### TRANSLATIONAL CANCER MECHANISMS AND THERAPY

**526** Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

Ying Jin, Yamei Chen, Huarong Tang, Xiao Hu, Shawna M. Hubert, Qian Li, Dan Su, Haimiao Xu, Yun Fan, Xinmin Yu, Qixun Chen, Jinshi Liu, Wei Hong, Yujin Xu, Huan Deng, Dapeng Zhu, Pansong Li, Yuhua Gong, Xuefeng Xia, Carl M. Gay, Jianjun Zhang, and Ming Chen

**540** Immune Profiling of Combined Hepatocellular-Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

Cong Trung Nguyen, Stefano Caruso, Pascale Maille, Aurélie Beaufrère, Jérémy Augustin, Loetitia Favre, Anais Pujals, Camille Boulagnon-Rom, Rami Rhaiem, Giuliana Amaddeo, Luca di Tommaso, Alain Luciani, Hélène Regnault, Raffaele Brustia, Olivier Scatton, Frédéric Charlotte, Isabelle Brochériou, Daniele Sommacale, Patrick Soussan, Vincent Leroy, Alexis Laurent, Van Ky Le, Van To Ta, Hong Son Trinh, Thi Lan Tran, David Gentien, Audrey Rapinat, Jean Charles Nault, Manon Allaire, Sebastien Mulé, Jessica Zucman-Rossi, Jean-Michel Pawlotsky, Christophe Tournigand, Fouad Lafdl, Valérie Paradis, and Julien Calderaro

**552** Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy

Shihong Peng, Pan Hu, Yu-Tian Xiao, Weiqiang Lu, Dandan Guo, Shixiu Hu, Jiayi Xie, SuFey Ong, Pascale Maille, Jean-Yves Scoazec, Stéphanie Vagner, and Caroline Robert

### ABOUT THE COVER

The cover shows a pathologic section of invasive, keratinizing squamous carcinoma from a patient with recurrent oral cavity or tongue cancer prior to neoadjuvant immunotherapy before salvage surgery. For details, see the article by Hanna and colleagues on page 468 of this issue.

doi: 10.1158/1078-0432.CCR-28-3-CVR